Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > BUSINESS
BUSINESS
- Sales of Januvia, Cervarix Exceed 50 Billion Yen in 2 Years since Launch
June 15, 2012
- DPP-4 Inhibitors Surged, RA Treatments Maintained Strong Growth in FY2011
June 15, 2012
- Top 100 Products in FY2011: Pronounced Growth for ARB Combinations with Declining Sales of Monodrugs
June 15, 2012
- Sanofi, Hisamitsu to Form JV for Allergy-Related OTCs, Seen Eyeing Allegra OTC Launch
June 14, 2012
- Janssen Pharmaceutical to Enlarge Plant Expecting 2.7 Times Current Shipping Volume
June 14, 2012
- Astellas to Collaborate with DNDi on Drug Discovery for Tropical Diseases
June 14, 2012
- MTPC to Launch Tenelia in Sept., Expecting to Become a Growth Driver: President Tsuchiya
June 14, 2012
- Midazolam is Most Used Sedative in Terminal Care: Doctor Survey
June 13, 2012
- Japan Vaccine to Develop, Supply All Vaccines Needed in Japan by 2020
June 13, 2012
- Astellas Launches Dificlir in Europe
June 13, 2012
- Sanofi-Aventis Files NDA for GLP-1 Receptor Agonist Lixisenatide in Japan
June 13, 2012
- Daiichi Sankyo Launches Olmesartan in Mexico
June 12, 2012
- Astellas Completes Enrollment for Global PIII Trial for MDV3100
June 12, 2012
- Sawai Considers Leveraging “MSs with MR Qualifications” with Medipal Group
June 12, 2012
- DSP Aims to Boost Latuda Sales with Add’l Indication of Bipolar Depression in US: President Tada
June 12, 2012
- IPV More Than Double Normal Cost for Japanese Market: Sanofi Pasteur
June 11, 2012
- DSP to Seek Additional Indication of Bipolar Depression for Latuda in US
June 11, 2012
- University of Tokyo Hospital to Take Over Development of Takeda’s AD Treatment Candidate
June 11, 2012
- Ethical Drug Sales Up 7.0% in April: Crecon Report
June 11, 2012
- 2012 MR Trend Survey
June 11, 2012
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
The Ministry of Health, Labor and Welfare (MHLW) posted the final report compiled by its pharmaceutical regulation panel on its website on April 24, providing cases of drugs that could be exempted from all-case post marketing surveillance (PMS).The MHLW plans…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…